All Stories

BridgeBio's ATTR-CM med Attruby gains traction, crushes analysts' early expectations

The company is going up against Pfizer's popular Vyndaqel franchise in the ATTR-CM field and has so far tallied 2,072 prescriptions since launching Attruby in December.

Apr 30, 2025 - 14:15
 0
BridgeBio's ATTR-CM med Attruby gains traction, crushes analysts' early expectations
The company is going up against Pfizer's popular Vyndaqel franchise in the ATTR-CM field and has so far tallied 2,072 prescriptions since launching Attruby in December.
Read More

Tags:

Previous Article

Charles Barkley boards Ro's GLP-1 ad push, signing up to take a 2nd shot at weig...

Next Article

Perinatal factors could play a role in heart health across the life span 

Related Posts

Akeso, Sino Biopharm’s Anniko enters crowded PD-1 market with FDA approval in head and neck cancer subtype

Akeso, Sino Biopharm’s Anniko enters crowded PD-1 marke...

Apr 25, 2025  0

Lupin recalls nearly 3,000 bottles of OCD medication in the US after subpar stability testing results

Lupin recalls nearly 3,000 bottles of OCD medication in...

Apr 24, 2025  0

Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending

Thermo Fisher jumps on the US investment bandwagon with...

Apr 24, 2025  0